Proteomics International Laboratories Ltd (ASX: PIQ) has inaugurated a state-of-the-art precision diagnostics testing laboratory at its facilities on the QEII Medical Campus in Perth, Western Australia to support its Australian commercialisation activities.
The laboratory has been upgraded with new cutting edge equipment and its accreditation extended to perform clinical pathology testing to ISO 15189 international standard by the Australian national testing authority, NATA. The opening represents a major step forward in Proteomics International’s mission to deliver world-class diagnostic technologies that improve Australian patient outcomes.
The new instrumentation provides sophisticated robotics and analytical instruments that expands the Company’s testing capacity for its suite of precision diagnostic blood tests. The capacity for its diabetic kidney disease prognostic will increase to 125,000 tests per annum, and capacity for its new Esophageal cancer and Endometriosis diagnostic tests will be up to 1,000 tests per day.
The Hon. Stephen Dawson MLC, Minister for Medical Research, Science and Innovation, will officially open the laboratory on November 25, 2025, alongside Dr. Richard Lipscombe, Managing Director of Proteomics International.
Left: Hon. Stephen Dawson MLC, Minister for Medical
Research, Science and Innovation. Right: Dr. Richard
Lipscombe, Managing Director of Proteomics International
"This advanced laboratory extends our significant test volume capacity to support the expansion of our precision diagnostics across Australia." said Dr. Lipscombe.
The new facility showcases Proteomics International’s state-of-the-art instrumentation and Promarker® diagnostic platform, which has earned global recognition for its ability to predict and diagnose chronic diseases using protein biomarkers.
About Proteomics International Laboratories Ltd (PILL) www.proteomics.com.au
Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of precision diagnostics and bio-analytical services. The Company specialises in the area of proteomics - the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.
Contact:
Managing Director
Dr Richard Lipscombe
Proteomics International
T: +61 8 9389 1992
E: enquiries@proteomics.com.au
Authorised by Dr Richard Lipscombe (Managing Director)